-
![Ben Comer_450x300]( "More Than A Seat At The Table")
More Than A Seat At The Table7/3/2023Bringing different perspectives together is important when debating industry policies, but the middle ground can still be allusive.
-
![Feature - Martin Mackay_450x300]( "From Biggest Pharma To Rare Disease Start-Up")
From Biggest Pharma To Rare Disease Start-Up6/1/2023Martin Mackay’s journey from Pfizer executive to founding and leading a rare disease biotech is a reflection of the industry’s evolution from a small molecule powerhouse to multimodal biotech.
-
![Ben Comer_450x300]( "More Transparency, To A Point")
More Transparency, To A Point6/1/2023New salary transparency laws are being enacted by a growing number of states, and more transparency is needed to address existing inequities. Is it possible to be too transparent?
-
![Feature #2 - Aulos Bioscience_450x300]( "Leading Aulos Bioscience's “Triumvirate” Model")
Leading Aulos Bioscience's “Triumvirate” Model6/1/2023Aulos Bioscience hopes to leverage its unique business model, engineered by a VC firm and an Israeli biotech, to develop better treatments for solid tumors.
-
![feature Fortress Bio_450x300]( "Fortress Biotech's Network Flex Business Model")
Fortress Biotech's Network Flex Business Model5/1/2023Fortress Biotech CEO Lindsay Rosenwald talks up Fortress Biotech’s business model, which leverages partner companies to develop promising but underexposed drug candidates.
-
![Feature - Cover - Dermatology Market_450x300]( "The Skin Is The Game: New Ways To Play In Dermatology")
The Skin Is The Game: New Ways To Play In Dermatology5/1/2023As the established indications in dermatology become saturated with competing products, a variety of companies, from start-ups to oncology players, are finding opportunities in underserved indications and reformulated drugs.
-
![Feature - Cover - Servier_450x300]( "Hitting The Ground Running In Oncology")
Hitting The Ground Running In Oncology4/3/2023David Lee, CEO at Servier Pharmaceuticals, talks about how he set up the French company’s U.S. division, and his goal of reaching $2 billion in annual oncology product revenue.
-
![Ben Comer_450x300]( "The Growing Appetite For Obesity Drugs")
The Growing Appetite For Obesity Drugs4/3/2023New obesity drugs with unprecedented efficacy are coming into the market. Can they turn the tide in the global obesity epidemic?
-
![Feature - Amarin_450x300]( "U.S. Patent Expired? Why Not Grow Revenue Globally, Says Amarin")
U.S. Patent Expired? Why Not Grow Revenue Globally, Says Amarin4/3/2023Amarin is deploying a global strategy to expand patient access to Vascepa, hoping to make up for lost revenues in the U.S.
Ben Comer
Ben Comer is chief editor of Life Science Leader magazine. He has covered the biopharmaceutical, medtech and medical device industries for 15 years as a reporter and editor, and worked as a senior manager in PwC’s Health Research Institute. Comer was most recently executive editor at In Vivo magazine, where he wrote feature stories, executive profiles and articles ranging from pre-clinical biotech strategy, fundraising, supply chain, manufacturing, and regulatory issues, to global commercialization efforts, market access and environmental, social and governance topics. He has interviewed hundreds of executives and experts at biopharmaceutical and life science companies, academic institutions, law firms, patient advocacy groups, payer and provider organizations, industry trade associations and regulatory bodies. Comer has presented and moderated panels at dozens of industry conferences, convened webcasts with industry leaders, and published news articles and other writing in Scrip, Pink Sheet, MedTech Insight, Generics Bulletin, Pharmaceutical Executive, PharmTech, Applied Clinical Trials, Medical Marketing & Media and PR Week, among others. Comer is a graduate of the College of Charleston and has worked in compounding pharmacies as a certified technician. You can find him on Twitter @BenMComer.